Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Could Vitamin C Help Stop Leukemia Before It Starts? (opens in a new tab)

scitechdaily.com · 2026-10-05

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One claim goes further than the study. 3 other points were not covered by the paper.

  • 5 supported
  • 1 overstated
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim overstates the study. Five of nine check out. Three claims the study doesn't address.

  • 5 supported
  • 1 overstated
  • 3 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

9 claims in this story

Showing all 9 claimsChoose a verdict to focus the list.

Claim 1 of 9OverstatedResults from the randomized, double-blind, placebo-controlled phase 2 EVITA trial found that participants who took 1,000 mg of oral vitamin C daily for one year experienced fewer adverse events during the study and follow-up period than those given a placebo.View evidenceHide evidence

As stated1,000 mg orally daily for one year; fewer adverse events

Why this verdict

The profile reports fewer serious adverse events in the vitamin C group during the 12-month treatment period. The story broadens this to fewer adverse events generally and extends it to the study and follow-up period, while the abstract profile does not provide support for general adverse events, statistical testing, or longer-term follow-up safety.

1

Study evidence

Fewer serious adverse events (SAEs) occurred in the vitamin C arm than in the placebo arm during the 12-month treatment period.18 of 55 (33%) in VitC vs 30 of 53 (57%) in placebo (as reported in abstract)

“secondary outcomes included ... fewer serious adverse events in the VitC group versus placebo (18 of 55 [33%] vs. 30 of 53 [57%]).”
Claim 2 of 9Not coveredA clinical trial suggests that correcting vitamin C deficiency may benefit people with certain blood disorders that can precede leukemia.View evidenceHide evidence

Why this verdict

The profile supports preliminary possible benefit signals from fewer serious adverse events and exploratory longer overall survival, but the abstract-level profile does not verify the claim’s framing around correcting vitamin C deficiency. It describes supplementation with vitamin C versus placebo, not a demonstrated benefit specifically from deficiency correction.

1

Study evidence

Fewer serious adverse events (SAEs) occurred in the vitamin C arm than in the placebo arm during the 12-month treatment period.18 of 55 (33%) in VitC vs 30 of 53 (57%) in placebo (as reported in abstract)

“secondary outcomes included ... fewer serious adverse events in the VitC group versus placebo (18 of 55 [33%] vs. 30 of 53 [57%]).”
2

Study evidence

In exploratory analyses of long-term follow-up, overall survival was longer with vitamin C than with placebo.HR 0.35 (95% CI 0.17 to 0.71); p = .0025

“followed by long-term follow-up”
Claim 3 of 9Not coveredThe findings, published in CANCER, showed that vitamin C changed levels of cytokines, and the changes were associated with more favorable outcomes and may indicate effects on pathways involved in abnormal blood cell growth.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that inflammatory cytokine trajectories differed between groups and that authors interpreted this as biological activity. However, it does not identify the cytokines, directions, magnitudes, statistical estimates, or any association of cytokine changes with more favorable outcomes or specific pathways involved in abnormal blood cell growth.

1

Study evidence

Secondary outcomes reported differences in inflammatory cytokine trajectories between the vitamin C and placebo arms over the trial period.

“secondary outcomes included differences in inflammatory cytokine trajectories”
Claim 4 of 9Not coveredMore than half of the participants were vitamin C deficient at baseline, and blood testing showed vitamin C levels normalized in those assigned to supplementation.View evidenceHide evidence

As statedmore than half deficient at baseline

Why this verdict

The abstract-level profile does not report baseline vitamin C deficiency prevalence or normalization of vitamin C levels after supplementation. This claim may depend on full-text details not present in the supplied abstract profile.

Claim 5 of 9SupportedResearchers are investigating whether restoring vitamin C levels can influence the biology of early blood disorders before leukemia develops.View evidenceHide evidence

Why this verdict

The abstract-level profile supports that EVITA investigated whether oral vitamin C affects biology in early-stage/precursor myeloid conditions, including clonal dynamics as the primary endpoint and cytokine trajectories as secondary biological activity signals. The story frames this as an investigation rather than a proven effect.

1

Study evidence

Twelve months of oral vitamin C (1000 mg/day) did not alter the median clonal growth rate compared with placebo in adults with CCUS or lower-risk myeloid malignancies.-0.016 (95% CI, -0.096 to 0.064); p = 0.70

“EVITA ... was a double-blind, randomized, placebo-controlled, phase 2 trial”
2

Study evidence

Secondary outcomes reported differences in inflammatory cytokine trajectories between the vitamin C and placebo arms over the trial period.

“secondary outcomes included differences in inflammatory cytokine trajectories”
Claim 6 of 9SupportedThe study included 109 people with clonal cytopenia of undetermined significance (CCUS) or myelodysplastic syndrome (MDS), both of which can progress to acute myeloid leukemia (AML).View evidenceHide evidence

As stated109 participants

Why this verdict

The profile reports 109 enrolled participants randomized to vitamin C or placebo and describes the population as adults with CCUS or lower-risk myeloid malignancies. The leukemia-progression framing is consistent with the profile’s description of early-stage myeloid malignancies/precursor conditions and preclinical rationale around leukemia progression.

1

Study evidence

Twelve months of oral vitamin C (1000 mg/day) did not alter the median clonal growth rate compared with placebo in adults with CCUS or lower-risk myeloid malignancies.-0.016 (95% CI, -0.096 to 0.064); p = 0.70

“EVITA ... was a double-blind, randomized, placebo-controlled, phase 2 trial”
2

Study evidence

In exploratory analyses of long-term follow-up, overall survival was longer with vitamin C than with placebo.HR 0.35 (95% CI 0.17 to 0.71); p = .0025

“followed by long-term follow-up”
Claim 7 of 9SupportedResearchers did not find a significant difference between the vitamin C and placebo groups in expansion of abnormal blood cell clones, a measure used to track progression toward leukemia.View evidenceHide evidence

Why this verdict

The profile states that the prespecified primary endpoint, median clonal growth rate from baseline to end of treatment, did not differ between vitamin C and placebo. This supports the story’s statement that abnormal clone expansion did not significantly differ between groups.

1

Study evidence

Twelve months of oral vitamin C (1000 mg/day) did not alter the median clonal growth rate compared with placebo in adults with CCUS or lower-risk myeloid malignancies.-0.016 (95% CI, -0.096 to 0.064); p = 0.70

“EVITA ... was a double-blind, randomized, placebo-controlled, phase 2 trial”
2

Study evidence

In exploratory analyses of long-term follow-up, overall survival was longer with vitamin C than with placebo.HR 0.35 (95% CI 0.17 to 0.71); p = .0025

“followed by long-term follow-up”
Claim 8 of 9SupportedAn exploratory analysis found that after about three years of follow-up, participants who received vitamin C were significantly more likely to be alive than those given a placebo, but the article says this needs confirmation in a larger phase 3 study.View evidenceHide evidence

As statedabout three years of follow-up; significantly more likely to be alive

Why this verdict

The profile supports that the overall survival finding came from exploratory long-term follow-up and was significantly longer with vitamin C, with a reported HR of 0.35 and p = .0025, and that authors said a phase 3 trial is warranted. The abstract profile does not verify the exact 'about three years' follow-up duration, so that timing detail is not confirmed at this evidence depth.

1

Study evidence

In exploratory analyses of long-term follow-up, overall survival was longer with vitamin C than with placebo.HR 0.35 (95% CI 0.17 to 0.71); p = .0025

“followed by long-term follow-up”
Claim 9 of 9SupportedThe article says laboratory and animal studies have suggested vitamin C can support remaining TET activity and may limit some cancer-related cellular changes.View evidenceHide evidence

Why this verdict

The profile states that vitamin C is a cofactor for TET enzymes involved in DNA demethylation and that preclinical data suggest vitamin C may delay leukemia progression. This supports the story’s hedged description of laboratory/animal rationale around TET activity and cancer-related cellular changes.

1

Study evidence

Twelve months of oral vitamin C (1000 mg/day) did not alter the median clonal growth rate compared with placebo in adults with CCUS or lower-risk myeloid malignancies.-0.016 (95% CI, -0.096 to 0.064); p = 0.70

“EVITA ... was a double-blind, randomized, placebo-controlled, phase 2 trial”
2

Study evidence

In exploratory analyses of long-term follow-up, overall survival was longer with vitamin C than with placebo.HR 0.35 (95% CI 0.17 to 0.71); p = .0025

“followed by long-term follow-up”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The cytokine finding is a secondary biological-activity signal: inflammatory cytokine trajectories differed between arms, but the abstract gives no cytokine identities, directions, magnitudes, p-values, or outcome-association details.

    The story mentions cytokine changes, but adds that the changes were associated with more favorable outcomes and may indicate effects on abnormal blood-growth pathways. Those added interpretive details are not verifiable from the abstract profile, and the story does not reflect the profile’s major limitations on cytokine detail.

    From Randomized, double-blind, placebo-controlled phase 2 trial

5 things the story did carry across
  • EVITA was a randomized, double-blind, placebo-controlled phase 2 trial of oral vitamin C 1000 mg/day versus placebo for 12 months in adults with CCUS or lower-risk myeloid malignancies.
  • The prespecified primary endpoint was median clonal growth rate from baseline to end of treatment, and it did not differ between groups.
  • Overall survival was longer with vitamin C only in exploratory long-term follow-up analyses, with limited abstract-level detail on follow-up duration, censoring, event counts, and modeling.
  • The paper’s authors frame the findings as preliminary phase 2 evidence and state that a phase 3 trial is warranted.
  • The preclinical rationale is that vitamin C is a TET cofactor involved in DNA demethylation and preclinical data suggest possible delay of leukemia progression.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEvaluate whether 12 months of oral vitamin C vs placebo alters clonal dynamics (clonal growth rate) in adults with CCUS or lower-risk myeloid malignancies.Phase 2 randomized double-blind placebo-controlled trialExpand

In plain English

Phase 2 double-blind randomized placebo-controlled trial (EVITA) testing whether 12 months of oral vitamin C (1000 mg/day) versus placebo alters clonal dynamics (median clonal growth rate) in adults with CCUS or lower-risk myeloid malignancies not receiving anticancer therapy. The primary endpoint (median clonal growth rate from baseline to end of 12-month treatment) did not differ between groups.

Key findings

  • Twelve months of oral vitamin C (1000 mg/day) did not alter the median clonal growth rate compared with placebo in adults with CCUS or lower-risk myeloid malignancies.-0.016 (95% CI, -0.096 to 0.064); p = 0.70
“EVITA ... was a double-blind, randomized, placebo-controlled, phase 2 trial”
What this piece can’t prove
  • Phase 2 trial; authors state a phase 3 trial is warranted to confirm findings.
2human in vivoAssess safety/tolerability of oral vitamin C vs placebo (including serious adverse events).Double-blind randomized placebo-controlled phase 2 trialExpand

In plain English

EVITA was a double-blind, randomized, placebo-controlled phase 2 trial comparing oral vitamin C (1000 mg/day) versus placebo for 12 months in adults with CCUS or lower-risk myeloid malignancies not receiving anticancer therapy. Safety/tolerability outcomes reported in the abstract indicate fewer serious adverse events (SAEs) in the vitamin C arm than placebo during the treatment period.

Key findings

  • Fewer serious adverse events (SAEs) occurred in the vitamin C arm than in the placebo arm during the 12-month treatment period.18 of 55 (33%) in VitC vs 30 of 53 (57%) in placebo (as reported in abstract)
“secondary outcomes included ... fewer serious adverse events in the VitC group versus placebo (18 of 55 [33%] vs. 30 of 53 [57%]).”
What this piece can’t prove
  • Abstract-only report: limited methodological detail on adverse event collection, definitions, and adjudication.
  • Relatively small sample size for safety endpoints (phase 2), limiting precision of effect estimates for harms.
  • Potential differences in follow-up or censoring between arms not described in abstract.

1 further detail could not be confirmed from the summary.

3human in vivoAssess biological activity signals of vitamin C vs placebo, including inflammatory cytokine trajectories.Randomized, double-blind, placebo-controlled phase 2 trialExpand

In plain English

In the EVITA randomized, double-blind, placebo-controlled phase 2 trial (oral vitamin C 1000 mg/day vs placebo for 12 months, n=109), the abstract reports secondary outcome differences in inflammatory cytokine trajectories between the vitamin C and placebo arms, interpreted as a biological activity signal. The abstract does not report which cytokines, the direction or magnitude of changes, or statistical estimates for these biomarker trajectories.

Key findings

  • Secondary outcomes reported differences in inflammatory cytokine trajectories between the vitamin C and placebo arms over the trial period.
“secondary outcomes included differences in inflammatory cytokine trajectories”
What this piece can’t prove
  • As a secondary outcome, the cytokine results may be exploratory; the abstract does not state whether these analyses were pre-specified or adjusted for multiple comparisons.

2 further details could not be confirmed from the summary.

4human in vivoExplore longer-term clinical outcomes after treatment, including overall survival, during follow-up.Double-blind, randomized, placebo-controlled phase 2 trial with long-term follow-up and exploratory time-to-event (overall survival) analysisExpand

In plain English

Exploratory long-term follow-up of the randomized, double-blind, placebo-controlled EVITA phase 2 trial (n=109) reports a longer overall survival with oral vitamin C (1000 mg/day for 12 months) versus placebo (exploratory HR 0.35; 95% CI 0.17–0.71; p = .0025). The analysis is labeled exploratory in the abstract; details on follow-up duration, censoring, and modeling are not provided there.

Key findings

  • In exploratory analyses of long-term follow-up, overall survival was longer with vitamin C than with placebo.HR 0.35 (95% CI 0.17 to 0.71); p = .0025
  • The primary trial endpoint, median clonal growth rate from baseline to end of treatment, showed no difference between vitamin C and placebo.-0.016 (95% CI -0.096 to 0.064); p = .70
“followed by long-term follow-up”
What this piece can’t prove
  • Abstract does not report follow-up duration, number of events, censoring patterns, or details of the survival model.
  • Phase 2 trial with relatively small randomized sample (n=109); event counts and power for survival differences not provided in abstract.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 34 candidate papers

SelectedOpen access

Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo-controlled trial.

Cancer · 2026 · PubMed, Europe PMC, Crossref

Tessa (opens in a new tab)Source (opens in a new tab)
Candidate

Author response for "Impact of mixed nut consumption on faecal lipid content and gut microbiota composition in healthy adults"

2026 · Crossref

Source (opens in a new tab)
Candidate

Author response for "Enhancing Photodynamic and Chemodynamic Therapy Efficacy through a Novel ROS-Amplifying Therapeutic Platform for Breast Cancer Treatment"

2026 · Crossref

Source (opens in a new tab)

And 28 more candidates considered.